Neoadjuvant Treatment, BRCA, PARP Inhibitors, FEATURED, News
Neoadjuvant Single-Agent PARP Inhibitor Appears Promising in BRCA Patients
BRCA patients may be able to take only one pill a day in a neoadjuvant setting The results of a small phase II trial suggest that the PARP inhibitor, talazopari...
